CS
DNLI icon

Credit Suisse’s Denali Therapeutics DNLI Stock Holding History

Credit Suisse’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$32.1M Sell
1,566,246
-9,975
-0.6% -$187K 0.03% 502
2023
Q4 		$33.8M Buy
1,576,221
+8,912
+0.6% +$177K 0.03% 502
2023
Q3 		$32.3M Sell
1,567,309
-5,739
-0.4% -$146K 0.03% 502
2023
Q2 		$46.4M Buy
1,573,048
+19,576
+1% +$550K 0.05% 426
2023
Q1 		$35.8M Buy
1,553,472
+20,089
+1% +$553K 0.04% 499
2022
Q4 		$42.6M Sell
1,533,383
-78,046
-5% -$2.32M 0.05% 441
2022
Q3 		$49.5M Sell
1,611,429
-348,596
-18% -$11.3M 0.06% 374
2022
Q2 		$57.7M Buy
1,960,025
+1,451
+0.1% +$38K 0.06% 340
2022
Q1 		$63M Sell
1,958,574
-5,074
-0.3% -$175K 0.05% 368
2021
Q4 		$87.6M Sell
1,963,648
-18,825
-0.9% -$892K 0.05% 414
2021
Q3 		$100M Buy
1,982,473
+15,965
+0.8% +$900K 0.06% 368
2021
Q2 		$154M Buy
1,966,508
+8,515
+0.4% +$527K 0.08% 253
2021
Q1 		$112M Buy
1,957,993
+555,243
+40% +$37.2M 0.06% 372
2020
Q4 		$117M Buy
1,402,750
+1,321,486
+1,626% +$79.9M 0.06% 356
2020
Q3 		$2.91M Sell
81,264
-21,383
-21% -$644K ﹤0.01% 2160
2020
Q2 		$2.48M Buy
102,647
+61,340
+148% +$1.44M ﹤0.01% 2212
2020
Q1 		$723K Sell
41,307
-697
-2% -$14.5K ﹤0.01% 2902
2019
Q4 		$732K Sell
42,004
-5,894
-12% -$98.1K ﹤0.01% 3335
2019
Q3 		$734K Buy
47,898
+6,711
+16% +$128K ﹤0.01% 3220
2019
Q2 		$854K Sell
41,187
-4,577
-10% -$103K ﹤0.01% 3053
2019
Q1 		$1.06M Buy
45,764
+1,673
+4% +$35K ﹤0.01% 2835
2018
Q4 		$910K Buy
44,091
+18,197
+70% +$330K ﹤0.01% 2856
2018
Q3 		$564K Buy
25,894
+13,960
+117% +$231K ﹤0.01% 3229
2018
Q2 		$181K Buy
+11,934
New +$225K ﹤0.01% 3781

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Credit Suisse's DNLI Position: Q1 2024 in Review

Credit Suisse reduced its Denali Therapeutics (DNLI) stake by 0.63% in Q1 2024, selling an estimated $187K and leaving 1,566,246 shares worth $32.1M. The position accounts for 0.03% of the portfolio, ranked #502.

Credit Suisse first reported a position in DNLI in Q2 2018 and has held it in 24 quarters since. The position peaked at $154M in Q2 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Credit Suisse held 1,566,246 shares of Denali Therapeutics worth $32.1M as of Q1 2024.
  • Credit Suisse sold 9,975 Denali Therapeutics shares in Q1 2024, an estimated $187K.
  • Denali Therapeutics made up 0.03% of Credit Suisse's portfolio in Q1 2024, its #502 holding.
  • Credit Suisse first reported a position in Denali Therapeutics in Q2 2018 and has held it in 24 quarters since.
  • Credit Suisse's Denali Therapeutics position peaked at $154M in Q2 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.